GALECTIN THERAPEUTICS INC
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting galectin proteins, which are key mediators of inflammation, fibrosis, and immune dysfunction. The company's website is www.galectintherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GALECTIN THERAPEUTICS INC does
In the company’s own words
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting galectin proteins, which are key mediators of inflammation, fibrosis, and immune dysfunction. The company's website is www.galectintherapeutics.com.
The company's lead product candidate is belapectin (GR-MD-02), a proprietary complex carbohydrate derived from naturally occurring plant products that binds and inhibits galectin-3. Belapectin is currently in clinical development for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and certain cancer indications. The company has completed two Phase 1 clinical studies, a Phase 2 trial in MASH patients with advanced fibrosis (NASH-FX), and a Phase 2b trial in MASH patients with compensated cirrhosis and portal hypertension (NASH-CX). Most recently, the company completed enrollment in the NAVIGATE Phase 2b/3 trial evaluating belapectin for prevention of esophageal varices in MASH cirrhosis patients, with top-line results presented in December 2024.
Beyond its lead indication, Galectin is pursuing belapectin in cancer immunotherapy, particularly for head and neck squamous cell carcinoma in combination with checkpoint inhibitors. The company filed an IND with the FDA in 2022 for this indication and received a Study May Proceed letter. Additionally, through its majority-owned joint venture subsidiary Galectin Sciences LLC, the company is developing small molecule galectin-3 inhibitors designed for oral administration to expand treatment potential beyond belapectin.
Galectin was founded in July 2000 as Pro-Pharmaceuticals Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. The company relocated its headquarters to the Atlanta area in 2012 while maintaining laboratory operations in the Boston region. As a development-stage company, Galectin outsources research, manufacturing, and clinical trial operations to third-party providers. During 2025, the company expended approximately 14.3 million dollars on research and development activities. The company is classified as a smaller reporting company and is not a well-known seasoned issuer.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NORCROSS, GA
- Fiscal year end
- December
- CIK
- 1133416
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GALECTIN THERAPEUTICS INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GALECTIN THERAPEUTICS INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GALECTIN THERAPEUTICS INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GALECTIN THERAPEUTICS INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GALECTIN THERAPEUTICS INC's last four quarterly filings that the numbers alone won't show?”